286 related articles for article (PubMed ID: 27455136)
41. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
Bartlett NL
Hematology Am Soc Hematol Educ Program; 2005; ():245-51. PubMed ID: 16304388
[TBL] [Abstract][Full Text] [Related]
42. Small lymphocytic lymphoma secondary to young patient with a history of classical Hodgkin Lymphoma.
Yan J; Cui F; Zhao S
Int J Lab Hematol; 2022 Feb; 44(1):31-33. PubMed ID: 34216429
[No Abstract] [Full Text] [Related]
43. What to Do With Deauville 3 Interim Positron Emission Tomography/Computed Tomography Response in a Young Woman With Classic Unfavorable Hodgkin's Lymphoma: To Irradiate or Not to Irradiate?
Farrugia MK; Vargo JA
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):13-14. PubMed ID: 31836075
[No Abstract] [Full Text] [Related]
44. Chemotherapy only for localized Hodgkin lymphoma.
Straus DJ
J Intern Med; 2011 Sep; 270(3):197-205. PubMed ID: 21668822
[TBL] [Abstract][Full Text] [Related]
45. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Carde P; Hagenbeek A; Hayat M; Monconduit M; Thomas J; Burgers MJ; Noordijk EM; Tanguy A; Meerwaldt JH; Le Fur R
J Clin Oncol; 1993 Nov; 11(11):2258-72. PubMed ID: 7693881
[TBL] [Abstract][Full Text] [Related]
46. [The optimal total focal radiotherapy dosage after first-line chemotherapy in patients with Hodgkin lymphoma].
Datsenko PV; Pan'shin GA; Sotnikov VM; Ivashin AV; Evstikheev ÉV; Golub SV; Gombolevskiĭ VA
Vopr Onkol; 2012; 58(4):527-31. PubMed ID: 23607209
[TBL] [Abstract][Full Text] [Related]
47. Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
Johnson PW
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):316-322. PubMed ID: 27913497
[TBL] [Abstract][Full Text] [Related]
48. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
49. Chemotherapy for Hodgkin's disease.
Ekert H
N Engl J Med; 2003 Sep; 349(12):1186-7; author reply 1186-7. PubMed ID: 13679536
[No Abstract] [Full Text] [Related]
50. Risk, cure and complications in advanced hodgkin disease.
Horning SJ
Hematology Am Soc Hematol Educ Program; 2007; ():197-203. PubMed ID: 18024630
[TBL] [Abstract][Full Text] [Related]
51. [Primary treatment of advanced Hodgkin's disease].
Illés A; Udvardy M; Molnár Z
Orv Hetil; 2005 Jan; 146(5):195-202. PubMed ID: 15773586
[TBL] [Abstract][Full Text] [Related]
52. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
Fizesan M; Boin C; Aujoulat O; Newinger G; Ghergus D; Watier H; Lustig H; Ojeda-Uribe M
J Oncol Pharm Pract; 2016 Feb; 22(1):188-92. PubMed ID: 25586990
[No Abstract] [Full Text] [Related]
53. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
54. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
55. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
56. [Relapse in Hodgkin lymphoma].
Filatova LV; Tarasenkova AA; Gershanovich ML; Semiglazov TIu
Vopr Onkol; 2012; 58(2):265-74. PubMed ID: 22774536
[TBL] [Abstract][Full Text] [Related]
57. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
von Tresckow B; Plütschow A; Fuchs M; Klimm B; Markova J; Lohri A; Kral Z; Greil R; Topp MS; Meissner J; Zijlstra JM; Soekler M; Stein H; Eich HT; Mueller RP; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2012 Mar; 30(9):907-13. PubMed ID: 22271480
[TBL] [Abstract][Full Text] [Related]
58. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
Diehl V; Engert A
Nat Clin Pract Oncol; 2006 May; 3(5):227. PubMed ID: 16682982
[No Abstract] [Full Text] [Related]
59. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
60. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
